Tilray Brands, Inc.
TLRY Healthcare Drug Manufacturers Specialty & Generic
Tilray Brands, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $915.5 million, up 11.5% from fiscal 2025. In the quarter to August 2026, revenue grew 22.7%, EPS was flat, free cash flow fell 36.6% and total debt rose 43.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TLRY
Tilray Brands, Inc. (TLRY) Piotroski F-score
Tilray Brands, Inc.'s Piotroski F-score for fiscal 2026 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2019.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 3 | 0.00 |
| FY2019 | 3 | 1.00 |
| FY2018 | 2 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (5.52%) | (69.46%) | Fail | 0 |
| Positive operating cash flow | (69.14m) | (94.60m) | Fail | 0 |
| Rising return on assets | (5.52%) | (69.46%) | Pass | 1 |
| Cash flow above net income | 52.25m | 2.09b | Pass | 1 |
| Falling long-term leverage | 0.16 | 0.10 | Fail | 0 |
| Rising current ratio | 2.21 | 2.46 | Fail | 0 |
| No new shares issued | 111,832,000 | 89,033,000 | Fail | 0 |
| Rising gross margin | 28.45% | 29.29% | Fail | 0 |
| Rising asset turnover | 0.42 | 0.26 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| KMDA Kamada Ltd. compare | 7 |
| EBS Emergent Biosolutions Inc. compare | 6 |
| CGC Canopy Growth Corporation compare | 5 |
| IRWD Ironwood Pharmaceuticals, Inc. compare | 5 |
| EVO Evotec AG compare | 5 |
| TKNO Alpha Teknova, Inc. compare | 5 |
| EOLS Evolus, Inc. compare | 3 |
| TLRY Tilray Brands, Inc. | 3 |
| AQST Aquestive Therapeutics, Inc. compare | 2 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover